The identification of DILA1 as a regulator of Cyclin D1 protein stability presents it as a promising therapeutic target for reducing Cyclin D1 levels and combatting tamoxifen resistance in breast cancer therapy, in line with the findings of Shi et al. (2020), we also observed an increased expression of Cyclin D1 and DILA1 in MCF7-TR cells compared to MCF10A and MCF7-S cells [5]. Here, CCND1 is linked to breast carcinoma.